Skip to main content

MoneyWorks4Me

Alkem Laboratories informs about press release

25 Sep 2023 Evaluate

Alkem Laboratories has informed that the Company and Biosergen AB (‘Biosergen’), have entered into a co-development and license agreement for the development and commercialization of Biosergen’s novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. A press release in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..